Back to top

oncology-screening: Archive

Zacks Equity Research

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC therapy, with strong early data in a pancreatic cancer study.

BAYRYNegative Net Change LXRXNegative Net Change AMRNPositive Net Change VSTMNegative Net Change

Ahan Chakraborty

RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?

Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.

SNYNegative Net Change LLYPositive Net Change SDGRPositive Net Change RXRXPositive Net Change

Zacks Equity Research

Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.

AZNNegative Net Change RHHBYNegative Net Change PFEPositive Net Change BAYRYNegative Net Change

Zacks Equity Research

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.

BMYNegative Net Change BAYRYNegative Net Change EXELPositive Net Change AMRNPositive Net Change

Zacks Equity Research

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.

JNJPositive Net Change MRKNegative Net Change IBRXPositive Net Change CGONPositive Net Change